ISO
Eurofins Genomics is committed to ensuring the highest quality standards so our customers always receive the best products and services. Click below to view our ISO accreditations.
With facilities in Europe, North America, and Asia, we support clients in the pharma, diagnostics, food, agriculture, biotechnological and research markets with services in DNA synthesis, DNA sequencing, gene synthesis, genotyping, and bioinformatics. Centrally managed content
High quality, single-stranded oligonucleotides applicable to almost any research field.
Huge assortment of custom probes for qPCR, dPCR, LNA, MGB applications and more.
The masters of complex gene constructs. Express service available for any gene.
Fast, affordable sequencing using the Oxford Nanopore platform for full plasmids, amplicons, bacterial genomes, and more.
The gold standard in sequencing with 99.9999% accuracy. We cover all Sanger needs including popular prepaid options.
From pre-designed packages to fully custom projects, we are the NGS provider of choice amongst researchers.
A variety of services including genotyping, gene expression, microarrays, and cell line authentication.
A new type of surveillance testing is providing macro-level data to cities across the world.
Eurofins Genomics is committed to ensuring the highest quality standards so our customers always receive the best products and services. Click below to view our ISO accreditations.
Oligonucleotides are manufactured according the globally recognised standard for quality management for the medical device industry.
ISO 9001 is the global quality management standard and the basis of Eurofins Genomics' QM/QA system.
ISO 17025 is an accredited standard measuring analytical excellence.
GMP (Good Manufacturing Practice) and GLP (Good Laboratory Practice) are globally-recognised quality standards for clinical and non-clinical.
We offer GMP (Good Manufacturing Practice) for both oligos and sequencing. GMP guarantees reliability, reproducibility, and traceability for your products or sequencing data.
Eurofins Genomics offers GLP (Good Laboratory Practice) sequencing, which is the gold-standard in confirming a sequence prior to publication or commercialisation.
FDA # 3009882691 approved for the manufacture of ASRs (Analyte Specific Reagents) for use in IVD products.
We offer unrivalled capabilities for quantification, impurity profiling, metabolite identification, radiolabel tracking, and structure elucidation. Centrally managed content
Before designing any study, we thoroughly explore the substance profile. This early analytical deep‑dive ensures fit-for-purpose, efficient, and scientifically justified study programmes — reducing avoidable testing and improving regulatory acceptance. Centrally managed content
1234567878
test test@mail.com
The Eurofins Discovery team was built by bringing together the market-leading discovery expertise of Panlabs (acquired in 2012 from Ricerca), Cerep (acquired in 2013), EMD Millipore's Discovery & Development Solutions business (acquired from Merck KGaA in 2014), Villapharma Research (acquired in 2017), DiscoverX (acquired in 2017), Selcia Drug Discovery (acquired in 2018), Beacon Discovery (acquired in 2021), DiscoveryBioMed (acquired in 2022), and Calixar (acquired in 2023). Eurofins Discovery comprises over 1,000 colleagues in seven sites across the world: St. Charles, MO (USA), Fremont, CA (USA), San Diego, CA (USA), Essex (UK), Celle Lévescault (France), Taipei (Taiwan), and Murcia (Spain). Our global team offers the high quality, reliable solutions and support our clients depend on to advance their drug discovery programmes. Centrally managed content
Test content body
Industries Centrally managed content